Aldeyra Therapeutics, Inc (NASDAQ:ALDX) – Cantor Fitzgerald issued their FY2019 earnings estimates for shares of Aldeyra Therapeutics in a research note issued on Thursday, October 17th. Cantor Fitzgerald analyst L. Chen anticipates that the biotechnology company will earn ($2.19) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $33.00 target price on the stock. Cantor Fitzgerald also issued estimates for Aldeyra Therapeutics’ FY2020 earnings at ($2.06) EPS.
Aldeyra Therapeutics (NASDAQ:ALDX) last announced its earnings results on Thursday, August 8th. The biotechnology company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.02.
Shares of Aldeyra Therapeutics stock opened at $5.96 on Monday. The firm’s fifty day simple moving average is $5.49 and its 200-day simple moving average is $6.29. The stock has a market capitalization of $161.07 million, a price-to-earnings ratio of -3.33 and a beta of 0.86. Aldeyra Therapeutics has a 12 month low of $4.31 and a 12 month high of $12.79.
A number of large investors have recently bought and sold shares of ALDX. Meeder Asset Management Inc. boosted its stake in shares of Aldeyra Therapeutics by 989.5% during the 3rd quarter. Meeder Asset Management Inc. now owns 10,448 shares of the biotechnology company’s stock valued at $54,000 after buying an additional 9,489 shares during the last quarter. D. E. Shaw & Co. Inc. purchased a new position in shares of Aldeyra Therapeutics during the 2nd quarter valued at approximately $67,000. Cubist Systematic Strategies LLC purchased a new position in shares of Aldeyra Therapeutics during the 2nd quarter valued at approximately $30,000. Point72 Asset Management L.P. purchased a new position in shares of Aldeyra Therapeutics during the 2nd quarter valued at approximately $1,950,000. Finally, Algert Global LLC boosted its stake in shares of Aldeyra Therapeutics by 28.6% during the 2nd quarter. Algert Global LLC now owns 29,840 shares of the biotechnology company’s stock valued at $179,000 after buying an additional 6,631 shares during the last quarter. Hedge funds and other institutional investors own 61.26% of the company’s stock.
In other news, Director Richard Douglas acquired 20,000 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were purchased at an average cost of $5.00 per share, for a total transaction of $100,000.00. Following the transaction, the director now directly owns 70,000 shares in the company, valued at approximately $350,000. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Todd C. Brady acquired 14,288 shares of the stock in a transaction that occurred on Wednesday, September 18th. The stock was purchased at an average price of $5.91 per share, for a total transaction of $84,442.08. Following the completion of the transaction, the chief executive officer now owns 614,826 shares in the company, valued at $3,633,621.66. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 83,907 shares of company stock worth $456,912. 13.50% of the stock is currently owned by insiders.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.
Further Reading: Momentum Indicators
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.